Stock ATXS ASTRIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Astria Therapeutics, Inc.

Equities

ATXS

US04635X1028

Real-time Estimate Cboe BZX
Other stock markets
 10:17:58 2024-04-24 am EDT 		5-day change 1st Jan Change
9.7 USD +0.62% Intraday chart for Astria Therapeutics, Inc. -10.05% +23.57%
Apr. 23 HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating MT
Apr. 09 Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating
MT
Astria Therapeutics : - 2024 Proxy Statement
PU
Astria Therapeutics : - 2023 Annual Report
PU
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
BU
Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee
CI
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Wedbush Raises Astria Therapeutics' PT to $22 From $17 After Reporting Top-Line Phase 1/2 ALPHA-STAR Results for STAR-0215 Program; Maintains Outperform Rating
MT
Transcript : Astria Therapeutics, Inc. - Special Call
Astria Therapeutics : Material Event - Form 8-K
PU
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
BU
Astria Therapeutics, Inc. Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
CI
North American Morning Briefing : Markets on Hold -2-
DJ
Astria Therapeutics, Inc.(NasdaqGM:ATXS) added to S&P Biotechnology Select Industry Index
CI
Certain Stock Options of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024.
CI
Certain Common Stock of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024.
CI
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
BU
Astria Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATXS Stock
  4. News Astria Therapeutics, Inc.